CliffBio
small molecule

VAZALORE

ASPIRIN

Loss of exclusivitySeptember 2032latest FDA-listed patent expiry
CompanyPLx Pharma →View the full company profile on CliffBio

Drug detail

Brand nameVAZALORE
Active ingredientASPIRIN
Strength81MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2021
Marketing statusOTC

Listed patents

PatentExpiresType
10786444September 2032use U-3559
10646431September 2032product

More from PLx Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VAZALORE patent cliff — loss of exclusivity September 2032 | CliffBio